Why the Same Merchant Gets Approved by One Acquirer and Rejected by Another

An acquiring decision reflects two risk profiles: the merchant’s and the portfolio receiving it.

That second profile explains a great deal of apparent inconsistency in payment underwriting. The same business can submit identical financials, processing history and compliance documents to two providers, receive a rejection from one and workable terms from the other. The difference may have little to do with the quality of the application.

Every acquirer operates within its own sponsor-bank policy, category exposure, geographic limits and network-monitoring position. A merchant that fits comfortably into one portfolio may create unwanted concentration in another.

Portfolio capacity shapes the decision

Consider an acquirer already carrying substantial exposure to subscription commerce. A new subscription merchant with acceptable dispute performance may still add more recurring-billing risk than the acquirer wants. The same calculation applies to travel, telemedicine, nutraceuticals and other categories with recognisable dispute or regulatory patterns.

The provider’s ability to monitor the category matters as well. An acquirer with experienced compliance staff and established controls can assess risks that a generalist provider may prefer to avoid altogether.

This affects pricing as much as approval. Two acquirers may accept the same merchant while offering very different reserves, settlement schedules and monthly caps. Those terms reflect the merchant’s record, but they also reflect the amount and type of exposure already sitting in each portfolio.

The organisation introducing the account may have limited control over this. An ISO, payment facilitator or processor can support an application, while the acquiring bank or sponsor bank still determines the underlying appetite.

VAMP exposes the portfolio mathematics

Visa’s Acquirer Monitoring Program provides a clear example.

Since April 1, 2026, the excessive merchant threshold in the United States, Canada, Europe and Asia-Pacific has been 1.5 percent, subject to a minimum monthly count of 1,500 fraud reports and disputes.

Acquirers are monitored at lower portfolio ratios. Visa classifies an acquirer portfolio as Above Standard at 0.50 percent and Excessive at 0.70 percent where the relevant minimum count is reached.

A merchant can therefore remain below the 1.5 percent merchant threshold and still be unattractive to an acquirer approaching its portfolio limit. The additional volume could increase network scrutiny, monitoring costs or the risk of remedial action across the wider book.

VAMP is one element among several. Sponsor-bank restrictions, fraud patterns, regulatory developments, geographic concentration and internal exposure limits can all influence the decision. Still, the thresholds show why a merchant’s own dispute ratio never provides the complete underwriting picture.

Mastercard’s merchant-monitoring framework follows the same portfolio logic. Its tools allow acquirers to assess individual merchant behaviour alongside wider exposure and to adjust risk tolerance by industry, geography or merchant segment.

Specialist underwriting produces a different answer

The effect is especially visible in categories that require more than a conventional financial review.

Research peptides are a useful example. One acquirer may reject the category because it lacks the sponsor-bank support or compliance expertise to supervise it. Another may review intended customers, product descriptions, certificates of analysis, marketing claims, refund terms and website language before reaching a decision.

Category experience does not rescue a weak or misleading business. It allows the underwriter to distinguish between materially different operations that share the same industry label.

Providers arranging research peptide merchant services may consequently request more documentation than a mainstream processor. A detailed review can still end in rejection, although it usually produces a more informed decision than a blanket response based on the category name.

The principle extends well beyond peptides. A telemedicine underwriter will focus on licensing, prescription controls and fulfilment. A nutraceutical specialist will examine ingredients, claims and recurring billing. A provider without those capabilities may have little commercial reason to enter either category.

Risk appetite moves even when the merchant does not

A bank that supported an industry last year may reduce or close its exposure today. Its sponsor may have changed policy, its dispute ratios may have deteriorated elsewhere, or its concentration in the category may have reached an internal limit.

The merchant may have changed nothing and still receive a different answer at renewal or when seeking a second account.

This also explains why the term “high risk” is so imprecise. It can describe the merchant’s actual performance, the characteristics of its industry, the limitations of a particular programme or the current condition of an acquirer’s portfolio. A short rejection email rarely reveals which one applies.

When comparing providers for high risk merchant accounts, merchants should ask which acquiring bank receives the application, whether that bank currently supports the category, and what volume, geography or dispute limits apply. They should also ask what changes could trigger a later review.

The useful underwriting question is more specific than “Is this merchant high risk?” It is: how does this merchant fit this acquirer’s portfolio, sponsor policy and remaining capacity?

That is why identical applications can produce opposite decisions, and why the cheapest initial offer may not represent the most durable acquiring relationship.